ANUH PHARMA
|
|
BOM : 506260     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
May 20,2022 |
Price(EOD): ₹ 99.10
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 496.49 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ANUH PHARMA | 4.2% | -1.3% | -36.1% |
SUN PHARMACEUTICAL INDUSTRIES | 3.4% | -0.8% | 28% |
DIVIS LABORATORIES | 2.1% | -3.3% | 4.4% |
DR REDDYS LABORATORIES | 9.2% | -1.1% | -24.4% |
CIPLA | 4.9% | -3.3% | 6.1% |
GLAND PHARMA | -1.3% | -6.3% | 1% |
PIRAMAL ENTERPRISES | 2.3% | -13.7% | 12% |
CADILA HEALTHCARE | 3.5% | -0.9% | -44% |
TORRENT PHARMACEUTICALS | 3.1% | -6.9% | -4.9% |
FUNDAMENTAL ANALYSIS OF ANUH PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ANUH PHARMA
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
17.48
P/E Calculated based on EPS of 5.67
[ Mar2021 - Standalone Results ] 2.61
P/B Calculated based on Book Value of 38.04
[ Mar2021 - Standalone Results ] 1.02
P/S Calculated based on Revenues of 486.646 Cr
[ TTM - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
158% 12% 9% |
SHARE PRICE MOMENTUM OF ANUH PHARMA
ANUH PHARMA vs SENSEX
DEBT OF ANUH PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.07 0.27 0.03 0.12 |
- - - - |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ANUH PHARMA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ANUH PHARMA
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-2.05% 14.3% 35.53% 19.83% |
32.76% 241.29% 626.61% 894.98% |
QtrlyTrend |
6 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
ANUH PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 4.1% | -8.7% | 16.8% |
S&P BSE MIDSMALLCAP | 3.7% | -8.4% | 12.6% |
S&P BSE ALLCAP | 3.2% | -5.8% | 10.3% |
S&P BSE HEALTHCARE | 2.8% | -6.4% | -4.8% |
You may also like the below Video Courses
FAQ about ANUH PHARMA
Is ANUH PHARMA good for long term investment?
As on May 20,2022, the Fundamentals of ANUH PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of ANUH PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ANUH PHARMA UnderValued or OverValued?
As on May 20,2022, ANUH PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of ANUH PHARMA ?
As on May 20,2022, the Intrinsic Value of ANUH PHARMA is Rs. 88.77 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 38.48
Fair Value [Median EV / Sales Model] : Rs. 88.77
Fair Value [Median Price / Sales Model] : Rs. 90.79
Median Fair Value of ANUH PHARMA : Rs. 88.77
Is ANUH PHARMA trading at a Premium or Discount?
As on May 20,2022, ANUH PHARMA is trading at a Premium of 12% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
